Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone510-265-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.47 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Aradigm (NASDAQ:ARDM) Frequently Asked Questions
What is Aradigm's stock symbol?
Aradigm trades on the NASDAQ under the ticker symbol "ARDM."
How were Aradigm's earnings last quarter?
Aradigm Co. (NASDAQ:ARDM) released its earnings results on Thursday, November, 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. The company had revenue of $0.28 million for the quarter. View Aradigm's Earnings History.
Has Aradigm been receiving favorable news coverage?
Headlines about ARDM stock have trended positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aradigm earned a daily sentiment score of 2.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the next several days.
Who are some of Aradigm's key competitors?
Some companies that are related to Aradigm include Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), CHF Solutions (CHFS), Reshape Lifesciences (RSLS), Escalon Medical (ESMC), Trimedyne (TMED), SpectraScience (SCIE), Guided Therapeutics (GTHP), Newcardio (NWCI), Magna-Lab (MAGAA), Echo Therapeutics (ECTE), 21st North (ULGX), IMRIS (IMRSQ), Nexeon Medsystems (NXNND) and Vision Sciences (CGNT).
What other stocks do shareholders of Aradigm own?
Who are Aradigm's key executives?
Aradigm's management team includes the folowing people:
- Dr. John M. Siebert, Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer (Age 79)
- Dr. Juergen Froehlich M.D., MBA, FCPh, Chief Medical Officer (Age 62)
- Dr. Igor Gonda, Consultant (Age 71)
- Ms. Nancy E. Pecota, Consultant (Age 59)
- Lisa Thomas, Corp. Controller
How do I buy shares of Aradigm?
Shares of ARDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aradigm's stock price today?
One share of ARDM stock can currently be purchased for approximately $0.10.
How big of a company is Aradigm?
Aradigm has a market capitalization of $1.52 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.
What is Aradigm's official website?
How can I contact Aradigm?
Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected]
MarketBeat Community Rating for Aradigm (NASDAQ ARDM)
MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
